Posted in | News | Nanomedicine | Nanomaterials

Discovery Could Shed Light on Pancreatic Diseases

Using a small boron-based molecule, glucagon-a hormone that plays a key role in pancreatic diseases-can now be imaged in live pancreatic cells. This breakthrough discovery was made by a team led by Young-Tae Chang from the Singapore Bioimaging Consortium of A*STAR*.

Fluorescent microscope images of unstained pancreatic alpha cells (top) and the same cells 24 hours after staining with glucagon yellow (bottom) (scale bar, 20 µm). Reproduced from Ref. 1 © 2009 The American Chemical Society

Produced in alpha cells of the pancreas, glucagon is a hormone peptide that, in partnership with insulin, maintains glucose levels in the blood. Glucagon production increases when the concentration of blood glucose decreases; an imbalance between insulin and glucagon results in diabetic disease.

Glucagon secretion has been studied extensively, but progress has been hampered by a lack of suitable probes for imaging the hormone in real time inside live cells and tissues. The current method, using antibodies, can only be used to take a snap shot of a dead cell. “Our glucagon probe can be used for imaging live cells, over a long period of time,” says Chang.

In their alternative approach, the team first made a library of small molecules consisting of a molecular component (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene, or BODIPY), which fluoresces when the molecule binds to glucagon directly attached to different chemical entities. The team selected 1,3-dimethyl-BODIPY as their fluorescent scaffold and reacted it with 238 different aromatic aldehydes in a microwave. This produced 160 compounds that were pure enough to be screened against live cells. This is the first report of a systematic construction of a library based on BODIPY, notes Chang.

The researchers assessed the compounds using an in vitro high-throughput screen against three different live cell lines-pancreatic alpha cells, pancreatic beta cells (which produce insulin), and control HeLa cells. From fluorescent images taken at different time intervals, they found that one of the compounds exhibited a selective and highly fluorescent response to the glucagon-secreting alpha cell line. They named this compound glucagon yellow, owing to its yellow fluorescence signal and selective fluorescence increase upon binding to glucagon (Fig. 1).

“Next we would like to find more alpha cell dyes, and also beta cell selective dyes,” Chang says. Through collaborations with positron emission tomography (PET) and single photon emission computed tomography (SPECT) experts at the Singapore Bioimaging Consortium, Chang also plans to try imaging the pancreas in situ using his team’s compounds. “The fluorescent molecule itself may not be a robust imaging probe in clinical applications,” but through team work he says “our dye will be converted in PET/SPECT probes, and will be applied to animal and clinical usage.”

The A*STAR affiliated authors in this highlight are from the Singapore Bioimaging Consortium

* Lee, J.-S., Kang, N.-Y., Kim, Y.K., Samanta, A., Feng, S., Kim, H.K., Vendrell, M., Park, J.H. & Chang, Y.-T. Synthesis of a BODIPY library and its application to the development of live cell glucagon imaging probe. Journal of the American Chemical Society 131, 10077–10082 (2009).

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.